Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Antibiotic Loaded Calcium Sulfate RCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03875963
Recruitment Status : Not yet recruiting
First Posted : March 15, 2019
Last Update Posted : March 25, 2019
Sponsor:
Collaborator:
Biocomposites, Ltd.
Information provided by (Responsible Party):
Lawson Health Research Institute

Brief Summary:
This is a multi-centered, prospective, randomized controlled trial comparing current standard of care for defect management to placement of antibiotic loaded Stimulan as a bone void filler in patients undergoing treatment of infected tibial defects or infected tibial nonunions.

Condition or disease Intervention/treatment Phase
Fracture Non Union Infection Other: Antibiotic loaded bone filler Not Applicable

Detailed Description:

There is a tremendous burden of disease associated with infected bone defects and infected nonunions and their management is challenging. Infected bone defects and nonunions have a profound clinical and economic impact and outcomes are limited by high rates of re-operation and poor functional outcomes. Reconstruction of infected bone defects or nonunions is difficult with multiple treatment options that may be considered. A comprehensive approach includes the treatment of infection, the management of dead space, skeletal stabilization, stimulation of soft tissue healing and healing of the bone defect or nonunion.

There is little evidence and a distinct lack of consensus regarding the definitive management of infected bone defects and infected nonunions. A two stage approach is still the gold standard for management and it remains unclear when alternative approaches should be considered. The first stage of the procedure includes adequate debridement, skeletal stabilization as required and placement of a polymethyl methacrylate cement spacer with or without antibiotics at the site of the bone defect. The second stage typically occurs between 6-8 weeks later with removal of the cement spacer and bone grafting into the preserved defect. There is no clear preferred management strategy and there remains a significant evidence gap.

There has been a significant interest in the use of bone graft substitutes for defect management as part of the management of infected bone defects and infected nonunions. The use of calcium sulfate as an alternative synthetic bone graft material has long been established (1-4), and the combination of calcium sulfate with antibiotics has been reported in the literature almost as long as antibiotics have been available (5, 6).

The clinical performance of calcium sulfate in combination with a single antibiotic, Tobramycin, is well documented (7, 8). However, in recent years, the use of calcium sulfate in combination with multiple antibiotics has grown in use as a means of providing protection from bacterial colonization by a wider variety of gram negative and gram positive pathogens (9-12). This study will evaluate the clinical performance of a high purity calcium sulfate bone void filler, STIMULAN® Rapid Cure. STIMULAN® Rapid Cure is intended to be gently packed into bony voids or gaps of the skeletal system (i.e., extremities, pelvis, and posterolateral spine). STIMULAN® Rapid Cure provides a bone graft substitute that resorbs and is replaced with bone during the healing process. STIMULAN® Rapid Cure is biodegradable and biocompatible and may be used at an infected site.

The proposed study is a multi-centered, prospective, randomized controlled trial, comparing current standard of care for defect management to placement of antibiotic loaded Stimulan as a bone void filler in patients undergoing treatment of infected tibial defects or infected tibial nonunions. Patients with an infected tibial bone defect or infected tibial nonunion meeting inclusion criteria will be randomized to receive either standard of care for defect management (Group A) or placement of antibiotic loaded Stimulan (10cc Stimulan Rapid Cure, 1g Vancomycin, 240mg Tobramycin) as a bone void filler (Group B), with a standardized intervention and post-intervention protocol.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The proposed study is a multi-centered, prospective, randomized controlled trial, comparing current standard of care for defect management to placement of antibiotic loaded Stimulan as a bone void filler in patients undergoing treatment of infected tibial defects or infected tibial nonunions.
Masking: Single (Outcomes Assessor)
Masking Description: Determination of union assessed by two independent assessors blinded to treatment arm
Primary Purpose: Treatment
Official Title: Performance of Antibiotic Impregnated Calcium Sulfate: A Prospective Randomized Controlled Trial
Estimated Study Start Date : April 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics Calcium

Arm Intervention/treatment
Experimental: Antibiotic loaded bone filler
Patients will undergo irrigation and debridement, surgical stabilization as required, and defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin]. The concurrent use of antibiotics is at the discretion of the treating physician.
Other: Antibiotic loaded bone filler
Defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin].

No Intervention: Standard of care
Current standard of care treatment for infected tibial defects or infected tibial nonunions includes treatment with irrigation and debridement, surgical stabilization as required, and defect management as required including placement of a polymethyl methacrylate spacer with or without antibiotics. A second procedure may or may not occur 6-8 weeks later with removal of the cement spacer and bone grafting into the preserved defect. Concurrent use of antibiotics is at the discretion of the treating physician.



Primary Outcome Measures :
  1. Number of re-operations [ Time Frame: 2 years post-injury ]
    Number of re-operations to obtain union or manage malunion, implant failure, or to eradicate infection.


Secondary Outcome Measures :
  1. Numeric Pain Rating Scale [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, and 24 months ]
    Pain measured using valid and reliable numeric pain rating scale. The scale measures the intensity of pain on a scale of 0 (meaning no pain) to 10 (worst pain). The scale asks the participant to rate the intensity of their pain in three ways -- their current pain level, their best pain level in the past 24 hours, and their worst pain level in the past 24 hours. The mean of all three scores is calculated by the research staff for a final average score. A lower score would indicate a better outcome, while a higher score would indicate a worse outcome.

  2. Functional Index In Trauma (FIX-IT) Measure [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, and 24 months ]
    The scale consists of two subscales - a weightbearing subscale and a pain subscale. The weight-baring subscale consists of two weight-bearing measures (Single Leg Score and Ambulation Score) and the pain subscale consists of two pain assessment measures (Palpation Score and Stress Score). Each of the four measures are rated on a scale from 0 to 3, with higher values representing a better outcome. For the weight bearing subscale, the Single Leg-Stand and the Ambulation Scores are added together, and for the pain subscale, the Palpation and the Stress Scores are added together for a total maximum score out of 6. The two subscales are added together at the end for a total maximum score of 12.

  3. Patient reported outcomes [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, and 24 months ]
    Short Musculoskeletal Function Assessment

  4. EuroQol Group Quality of Life Scale with 5 Dimensions and 5 Levels (EQ-5D-5L) [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, and 24 months ]
    The EuroQol5D-5L measures overall health and quality of life in 5 dimensions - Mobility, Self-care, Usual Activities, Pain/Discomfort, Anxiety/Depression. Each subscale is given a score from 0 to 4, with higher scores representing a worse outcome. The 5 subscale scores are added together for a total maximum score out of 20. There is one additional question which asks the participant to rate their overall perceived health today on a scale from 0 to 100 with 0 representing the worst health they can imagine and 100 representing the best health they can imagine.

  5. Number of patients with complications [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, and 24 months ]
    Complications assessed will include nonunion, malunion, leg length discrepancy, infection, wound healing problems, and drainage

  6. Economic analysis [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, and 24 months ]
    Ambulatory and Health Care Record to record economic burden on patient

  7. Radiographic assessment [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, and 24 months ]
    a) Anteroposterior and lateral tibial x-rays of all patients will be obtained at the standard follow-up intervals and will be blinded and scored by two established orthopaedic surgeons who are familiar with the RUST and modified RUST assessment scales b) Defect size pre-treatment will be measured using anteroposterior and lateral tibial x-rays



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥16 years old.
  • Isolated infected tibia defect or infected tibial nonunion (characterized by clinical symptoms present for greater than 90 days, the presence of necrotic bone, and bacteria cultured from prior procedures, surgical biopsy, or draining sinuses).

Exclusion Criteria:

  • Presence of previous vascular injury or pathologic fracture
  • Associated lower limb injuries that would interfere with rehabilitation or outcome - Refusal to participate; - Inability to provide informed consent
  • Inability to speak/understand or read English without a registered interpreter.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03875963


Contacts
Layout table for location contacts
Contact: Emil Schemitsch, MD FRCS(C) 519-685-8500 ext 33307 Emil.Schemitsch@lhsc.on.ca
Contact: Adrienne E Borrie, PhD 519-685-8500 ext 35834 Adrienne.Borrie@lhsc.on.ca

Sponsors and Collaborators
Lawson Health Research Institute
Biocomposites, Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Emil Schemitsch, MD FRCS(C) London Health Sciences Centre

Publications:

Layout table for additonal information
Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT03875963     History of Changes
Other Study ID Numbers: 5148
First Posted: March 15, 2019    Key Record Dates
Last Update Posted: March 25, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Lawson Health Research Institute:
Infection
Antibiotic bone cement
Tibia nonunion

Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Bacterial Agents
Antibiotics, Antitubercular
Fractures, Ununited
Fractures, Bone
Wounds and Injuries
Calcium
Calcium, Dietary
Anti-Infective Agents
Antitubercular Agents
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents